Literature DB >> 20185188

Characterization of ribavirin uptake systems in human hepatocytes.

Yukina Fukuchi1, Tomomi Furihata, Misato Hashizume, Minami Iikura, Kan Chiba.   

Abstract

BACKGROUND & AIMS: The purpose of this study was to identify the major ribavirin uptake transporter(s) in human hepatocytes and to determine if these previously unidentified transporters are involved in hepatic ribavirin uptake. Furthermore, we aimed to address what causes the difference in uptake levels among human hepatocytes.
METHODS: Profiles of ribavirin uptake and nucleoside transporter mRNA expression in Caucasian hepatocytes (HH268, HH283 and HH291) were characterized by transport assay and reverse transcription-polymerase chain reaction (RT-PCR). The 5'-side of the SLC29A1 gene structure was characterized by determination of transcription start sites and by RT-PCR.
RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. The level of ENT1-mediated uptake in HH291 was higher than that in HH268 and HH283. Characterization of the SLC29A1 gene structure revealed the existence of several ENT1 mRNA isoforms in the human liver, and the levels of four ENT1 mRNA isoforms in HH291 were higher than those in HH268 or HH283. No ENT2-mediated uptake was observed in any hepatocyte lines. Na(+)-dependent uptake was detected only in HH291; however, mRNA levels of concentrative nucleoside transporters (CNTs) were at trace levels in all hepatocyte lines.
CONCLUSIONS: ENT1, but not ENT2 or CNTs, is a major ribavirin uptake transporter in human hepatocytes. The different ENT1-mediated ribavirin uptake levels in different hepatocyte lines are associated with different expression levels of specific isoforms of ENT1 mRNAs. Furthermore, an unidentified Na(+)-dependent ribavirin transport system might exist in human hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185188     DOI: 10.1016/j.jhep.2010.01.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

2.  Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.

Authors:  Darius Babusis; Michael P Curry; Brian Kirby; Yeojin Park; Eisuke Murakami; Ting Wang; Anita Mathias; Nezam Afdhal; John G McHutchison; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.

Authors:  Tomomi Furihata; Yukina Fukuchi; Minami Iikura; Misato Hashizume; Atsushi Miyajima; Miki Nagai; Kan Chiba
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

4.  ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.

Authors:  Minami Iikura; Tomomi Furihata; Misa Mizuguchi; Miki Nagai; Masanori Ikeda; Nobuyuki Kato; Akihito Tsubota; Kan Chiba
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

5.  Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.

Authors:  Kristie D Ibarra; Mamta K Jain; Julie K Pfeiffer
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Vaginal ecosystem modeling of growth patterns of anaerobic bacteria in microaerophilic conditions.

Authors:  Audrie A Medina-Colorado; Kathleen L Vincent; Aaron L Miller; Carrie A Maxwell; Lauren N Dawson; Trevelyn Olive; Elena V Kozlova; Marc M Baum; Richard B Pyles
Journal:  Anaerobe       Date:  2017-04-26       Impact factor: 3.331

7.  Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.

Authors:  Nirav R Shah; Amanda Sunderland; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

8.  Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin.

Authors:  Kanwal Baloch; Liqiong Chen; Ameer A Memon; Laura Dexter; William Irving; Mohammad Ilyas; Brian J Thomson
Journal:  Antivir Chem Chemother       Date:  2017-01-01

Review 9.  Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

Review 10.  Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.

Authors:  Clara T M M de Kanter; Joost P H Drenth; Joop E Arends; Henk W Reesink; Marc van der Valk; Robert J de Knegt; David M Burger
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.